Literature DB >> 17637824

Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population.

Ying Jin1, Stanca A Birlea, Pamela R Fain, Richard A Spritz.   

Abstract

Generalized vitiligo is a common, multifactorial, polygenic disease in which autoimmune loss of melanocytes results in depigmented spots of skin, overlying hair, and mucous membranes. In Caucasian families from the United States of America and United Kingdom, susceptibility to generalized vitiligo and associated autoimmune diseases is genetically associated with variants of NALP1, encoding NACHT leucine-rich repeat protein 1. Here, we describe a population-based case-control association analysis of single-nucleotide polymorphisms (SNPs) distributed through the NALP1 region in Caucasian generalized vitiligo patients and controls from Romania. This study confirms genetic association of generalized vitiligo with variation in NALP1, which contains at least two independent risk signals, one tagged by SNP rs6502867 and another tagged by SNPs rs2670660 and rs8182352. Individuals carrying high-risk alleles of both rs6502867 and rs2670660 had an odds ratio of 4.20 compared with individuals carrying a high-risk allele from only one signal. These findings support the involvement of NALP1 in predisposition to generalized vitiligo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637824     DOI: 10.1038/sj.jid.5700953

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  42 in total

Review 1.  Pattern recognition receptors in immune disorders affecting the skin.

Authors:  Heleen D de Koning; Anna Simon; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Innate Immun       Date:  2012-03-06       Impact factor: 7.349

Review 2.  Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease.

Authors:  Richard A Spritz
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

Review 3.  The role of the inflammasome in nonmyeloid cells.

Authors:  Amir S Yazdi; Stefan K Drexler; Jürg Tschopp
Journal:  J Clin Immunol       Date:  2010-06-27       Impact factor: 8.317

4.  The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis.

Authors:  Tere M Williams; Rachel A Leeth; Daniel E Rothschild; Sheryl L Coutermarsh-Ott; Dylan K McDaniel; Alysha E Simmons; Bettina Heid; Thomas E Cecere; Irving C Allen
Journal:  J Immunol       Date:  2015-02-27       Impact factor: 5.422

Review 5.  NLR proteins: integral members of innate immunity and mediators of inflammatory diseases.

Authors:  Jeanette M Wilmanski; Tanja Petnicki-Ocwieja; Koichi S Kobayashi
Journal:  J Leukoc Biol       Date:  2007-09-17       Impact factor: 4.962

Review 6.  Inflammasomes: too big to miss.

Authors:  Andrea Stutz; Douglas T Golenbock; Eicke Latz
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

Review 7.  Genetic and molecular basis of inflammasome-mediated disease.

Authors:  Hal M Hoffman; Susannah D Brydges
Journal:  J Biol Chem       Date:  2011-02-04       Impact factor: 5.157

Review 8.  Deregulated inflammasome signaling in disease.

Authors:  Mohamed Lamkanfi; Lieselotte Vande Walle; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

9.  CTLA4 and generalized vitiligo: two genetic association studies and a meta-analysis of published data.

Authors:  Stanca A Birlea; Greggory S Laberge; Lucia M Procopciuc; Pamela R Fain; Richard A Spritz
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-17       Impact factor: 4.693

10.  NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome.

Authors:  Cecilia B Levandowski; Christina M Mailloux; Tracey M Ferrara; Katherine Gowan; Songtao Ben; Ying Jin; Kimberly K McFann; Paulene J Holland; Pamela R Fain; Charles A Dinarello; Richard A Spritz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.